At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
APL-130277 +2 moredrug
Likely dose
Moxifloxacin 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
In Brief
A Phase 2 clinical trial evaluating APL-130277, Placebo, and 1 other intervention for Parkinson's Disease and Off Episodes of Parkinson Disease. Completed, enrolled 48 participants across 15 sites in 2 countries.
Detailed Summary
A cardiac safety study of an investigational drug to see how it affects the heart in people with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartAug 2017
Primary CompletionDec 2017
TodayJul 2026
First PostedJun 14, 2017
Enrollment StartAug 3, 2017
Primary CompletionDec 21, 2017
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.0 years ago
Interventions
APL-130277drug
APL-130277 single dose
Placebodrug
Placebo single dose
Moxifloxacindrug
moxifloxacin 400mg single dose